Simponi (Golimumab) Patent Expiration, LOE Window & CMS Spending

Simponi (Golimumab) by Johnson & Johnson: Biologic BLA (Purple Book Regime), 0 AB generics, $246.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayB125289 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$246.8M
2024 Medicare Part D Spend$184.7M
2024 Medicaid Spend$62.1M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 16.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.